Structural Heart (Apr 2022)

Cardiac Damage Staging Classification in Asymptomatic Moderate or Severe Primary Mitral Regurgitation

  • Jérémy Bernard, MSc,
  • Alexandre Altes, MD,
  • Marlène Dupuis, MSc,
  • Oumhani Toubal, MD,
  • Haïfa Mahjoub, MD, PhD,
  • Lionel Tastet, MSc,
  • Nancy Côté, PhD,
  • Marie-Annick Clavel, DVM, PhD,
  • Hélène Dumortier, MD,
  • Jean Tartar, MD,
  • Kim O'Connor, MD,
  • Mathieu Bernier, MD,
  • Jonathan Beaudoin, MD,
  • Sylvestre Maréchaux, MD, PhD,
  • Philippe Pibarot, DVM, PhD

Journal volume & issue
Vol. 6, no. 1
p. 100004

Abstract

Read online

Background: Optimal timing for intervention remains uncertain in asymptomatic patients with primary mitral regurgitation (MR). We aimed to assess the prognostic value of a new cardiac damage staging classification in patients with asymptomatic moderate or severe primary MR. Methods: Clinical, Doppler-echocardiographic, and outcome data prospectively collected in 338 asymptomatic patients (64 ± 15 years, 68% men) with at least moderate primary MR were retrospectively analyzed. Patients were hierarchically classified as per the following staging classification: no cardiac damage (stage 0), mild left ventricular or left atrial damage (stage 1), moderate or severe left ventricular or left atrial damage (stage 2), pulmonary vasculature or tricuspid valve damage (stage 3), or right ventricular damage (stage 4). Results: There was a stepwise increase in 10-year mortality rates as per cardiac damage stage: 20.0% in stage 0, 25.6% in stage 1, 31.5% in stage 2, and 61.3% in stage 3-4 (p < 0.001). The staging classification was significantly associated with increased risk of mortality (hazard ratio = 1.41 per one-stage increase, 95% confidence interval: 1.07-1.85, p = 0.015) and the composite of cardiovascular mortality or hospitalization (hazard ratio = 1.51 per one-stage increase, 95% confidence interval: 1.07-2.15, p = 0.020) in multivariable analysis adjusted for EuroSCORE II, mitral valve intervention as a time-dependent variable, and other risk factors. The proposed scheme showed incremental value over several clinical variables (net reclassification index = 0.40, p = 0.03). Conclusions: The new staging classification provides independent and incremental prognostic value in patients with asymptomatic moderate or severe MR.

Keywords